A5003885788- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Hepatitis B Virus Studies
- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- SARS-CoV-2 and COVID-19 Research
- Tuberculosis Research and Epidemiology
- Liver Disease and Transplantation
- Liver Diseases and Immunity
- Hepatitis Viruses Studies and Epidemiology
- Diagnosis and treatment of tuberculosis
- Pneumocystis jirovecii pneumonia detection and treatment
- COVID-19 diagnosis using AI
- Hepatocellular Carcinoma Treatment and Prognosis
- COVID-19 and healthcare impacts
- HIV/AIDS drug development and treatment
- Cardiac Imaging and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Systemic Lupus Erythematosus Research
- Pancreatitis Pathology and Treatment
- Advanced Glycation End Products research
- Respiratory Support and Mechanisms
- Immunodeficiency and Autoimmune Disorders
- Drug-Induced Adverse Reactions
- Lipid metabolism and disorders
Wroclaw Medical University
2016-2025
Łukasiewicz Research Network – PORT Polish Center for Technology Development
2013-2025
Klinikum Region Hannover
2025
Harvard University
2010-2025
University of Wrocław
2007-2025
Massachusetts General Hospital
2025
Roswell Park Comprehensive Cancer Center
2025
Medical University of Warsaw
2012-2024
Wojewódzki Szpital Specjalistyczny we Wrocławiu
2021-2024
Szpital Kliniczny Nr 1 we Wrocławiu
2022
The aim of this study was to evaluate cenicriviroc (CVC), a dual antagonist CC chemokine receptor types 2 and 5, for treatment nonalcoholic steatohepatitis (NASH) with liver fibrosis (LF). A randomized, double‐blind, multinational phase 2b enrolled subjects NASH, fatty disease activity score (NAS) ≥4, LF (stages 1‐3, NASH Clinical Research Network) at 81 clinical sites. Subjects (N = 289) were randomly assigned CVC 150 mg or placebo. Primary outcome ≥2‐point improvement in NAS no worsening...
Peginterferon alfa-2a results in a sustained response (SR) minority of patients with hepatitis B e antigen (HBeAg)–negative chronic (CHB). This study investigated the role early on-treatment serum surface (HBsAg) levels prediction SR HBeAg-negative receiving peginterferon alfa-2a. HBsAg (Architect from Abbott) was quantified at baseline and during treatment (weeks 4, 8, 12, 24, 36, 48) follow-up 60 72) sera 107 who participated an international multicenter trial (peginterferon alfa-2a, n =...
Entecavir (ETV) is a potent inhibitor of hepatitis B viral replication, but long‐term therapy may be required. We investigated whether adding on pegylated interferon (Peg‐IFN) to ETV enhances serological response rates. In this global investigator‐initiated, open‐label, multicenter, randomized trial, e antigen (HBeAg)‐positive chronic (CHB) patients with compensated liver disease started monotherapy (0.5 mg/day) and were in 1:1 ratio either Peg‐IFN add‐on (180 µg/week) from week 24 48 (n =...
Thrombocytopenia may be associated with increased bleeding risk impacting timing and outcome of invasive procedures in patients chronic liver disease (CLD). Lusutrombopag, a small‐molecule, thrombopoietin (TPO) receptor agonist, was evaluated as treatment to raise platelet counts (PCs) thrombocytopenia CLD undergoing procedures. L‐PLUS 2 global, phase 3, randomized, double‐blind, placebo‐controlled study. Adults baseline PCs < 50 × 10 9 /L were randomized receive once‐daily lusutrombopag...
Virologic and safety outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ribavirin (OBV/PTV/r DSV RBV) therapy have shown high sustained virologic response (SVR) rates good tolerability in most patient populations pre-registration studies.To confirm these clinical trial findings the treatment genotype 1 4 hepatitis C under real-world conditions.Patients enrolled for with OBV/PTV/r RBV based on therapeutic guidelines were included, regimen was administered according to product...
Hepatitis B e antigen (HBeAg)-negative chronic hepatitis patients are at high risk of treatment relapse after any antiviral therapy. Combining peginterferon alpha-2a with ribavirin might improve sustained response rates.Overall, 138 HBeAg-negative were randomized to receive monotherapy (peginterferon 180 microg weekly plus placebo) or combination therapy 1,000 1,200 mg daily, depending on body weight) for 48 weeks. Post-treatment follow-up lasted 24 Analyses based the modified...
Peginterferon (PEG-IFN) treatment of hepatitis B e antigen (HBeAg)-positive chronic (CHB) results in HBeAg loss 30% patients, but clearance virus (HBV) DNA and surface (HBsAg) from serum is less often achieved. We investigated whether the presence precore (PC) basal core promoter (BCP) mutants before PEG-IFN affects serological virological response. A total 214 HBeAg-positive CHB patients treated with PEG-IFN±lamivudine for 52 weeks a global randomized trial were classified at baseline as...
Nonalcoholic fatty liver disease (NAFLD), an escalating health problem worldwide, covers a spectrum of pathologies characterized by accumulation in hepatocytes early stages, with potential progression to inflammation, fibrosis, and failure. A close, yet poorly understood link exists between NAFLD dyslipidemia, constellation abnormalities plasma lipoproteins including triglyceride-rich very low density lipoproteins. Apolipoproteins are group primarily liver-derived proteins found serum...
The first Polish recommendations regarding the management of patients with COVID-19 were published by Society Epidemiologists and Infectiologists (PTEiLChZ) on March 31, 2020, last annex was dated November 12, 2021. ongoing state pandemic, emergence new variants virus, availability drugs necessitate their updating. Changes introduced in current version for comprised possibility using remedesivir an outpatient setting, previously reserved inpatient treatment, as well other antiviral...
On-treatment decline of serum hepatitis B surface antigen (HBsAg) may reflect the immunomodulatory effect pegylated interferon (PEG-IFN) for e (HBeAg)-positive chronic (CHB). We compared HBsAg across HBV genotypes between combined responders (HBeAg loss and DNA<10,000 copies/ml at week 78), HBeAg with DNA>10,000 copies/ml) non-responders.HBsAg was measured baseline, on-treatment 6 months post-treatment in 221 HBeAg-positive CHB patients treated PEG-IFN or without lamivudine 52 weeks, a...
According to small studies carried out in preselected populations, the estimated prevalence of anti-hepatitis C virus (HCV) antibodies Poland ranges from 0.6 2.1%.The aim this study was evaluate anti-HCV and HCV RNA among patients healthcare workers.Anti-HCV were measured (Elecsys, Roche) serum samples 26,057 adults, consecutive or workers, hospitals patient clinics not involved management liver diseases. The majority them (18,233) consented fill an anonymous questionnaire related possible...
The clinical trials of the COVID-19 vaccines that are authorized in European Union have revealed high efficacy preventing symptomatic infections. However, during vaccination campaigns, some vaccine recipients, including those partially and fully vaccinated, will experience severe COVID-19, requiring hospitalization. This may particularly concern patients with a diminished immune response to vaccine, as well non-responders. work has retrospectively analyzed 92 cases who were hospitalized...
Summary Background : Treatment with interferon‐alpha has been shown to be effective in one‐third of hepatitis B e antigen‐positive chronic patients, but is clinically associated relevant adverse events. Aim To investigate the safety pegylated interferon alpha‐2b 300 patients compensated liver disease. Methods Patients were treated for 52 weeks combined either lamivudine 100 mg/day or placebo. Pegylated was administered μ g once a week 32 weeks; thereafter, dose reduced 50 week. Adverse...
In chronic hepatitis B, it is difficult to predict an early therapeutic response. We investigated the viral decline during therapy with pegylated interferon alpha-2b (PEG-IFN) or without lamivudine in 266 HBeAg-positive B patients. patients treated PEG-IFN and lamivudine, a uniform biphasic pattern was found there were no marked differences load between those who lost HBeAg at end of follow-up (response) not. contrast, monotherapy exhibited different patterns. A delayed least two log from...